PMC:7696151 / 85242-85395
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 2547 | 48-60 | Chemical | denotes | temsirolimus | MESH:C401859 |
| 2548 | 82-85 | Chemical | denotes | HCQ | MESH:D006886 |
| 2569 | 134-139 | Disease | denotes | tumor | MESH:D009369 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T211 | 134-139 | Phenotype | denotes | tumor | http://purl.obolibrary.org/obo/HP_0002664 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T542 | 0-153 | Sentence | denotes | In both cases, the standard intravenous dose of temsirolimus with 1200 mg of oral HCQ was considered safe and tolerated and inhibited tumor growth [167]. |